$0.00
Shopping Cart
Facebook-f Instagram
DONATE
Donate

Clinical Trial Record

Return to Clinical Trials

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

2018-09-17

2021-09-17

2022-09-17

30

Study Overview

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Using alternative neoadjuvant gemcitabine-nab-paclitaxel and nal-IRI with 5-Fluorouracil (5FU) and folinic acid (Leucovorin) regimens of localized cancer, we hope to ensure exposure of the cancer to a broader array of potentially active agents. Also, potentially improves patient tolerance and minimizes significant drug toxicity that could impair delivery of all treatment elements. Furthermore, it may enable prediction of superior to inferior treatment outcomes at an earlier point in the disease progress.

This research study is a Phase Ib clinical trial. It will assess the Safety, tolerability, and feasibility of gemcitabine-nab paclitaxel alternating with nal-IRI/5FU/leucovorin (NAPOLI) in de novo resectable and borderline resectable pancreatic cancer. Subjects must have a newly diagnosed resectable or borderline resectable pancreatic ductal cancer and meet all inclusion/exclusion criteria. Treatment consists of 4 week treatment cycles. Nab-paclitaxel and gemcitabine will be administered on days 1,8, and 15 with NAPOLI will be administered on days 1 and 15.

  • Pancreatic Adenocarcinoma
  • DRUG: Gemcitabine
  • DRUG: nab paclitaxel
  • DRUG: Onivyde
  • DRUG: Leucovorin
  • DRUG: 5-fu
  • CRP17118

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2018-10-08  

N/A  

2021-01-25  

2018-10-09  

N/A  

2021-01-27  

2018-10-11  

N/A  

2021-01  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Treatment

Allocation:
Non Randomized

Interventional Model:
Parallel

Masking:
None

Arms and Interventions

Participant Group/ArmIntervention/Treatment
EXPERIMENTAL: Resectable patients

Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucov

DRUG: Gemcitabine

  • Administered by intravenous infusion over 30 minutes.

DRUG: nab paclitaxel

  • Administered by intravenous infusion over 30-40 minutes.

DRUG: Onivyde

  • Administered by intravenous infusion over 90 minutes.

DRUG: Leucovorin

  • Administered by intravenous infusion over 30 minutes.

DRUG: 5-fu

  • Administered by intravenous infusion over 46 hours.
EXPERIMENTAL: Borderline resectable patients

Gemcitabine and Nab-Paclitaxel Participants received albumin-bound paclitaxel 125 mg/m^2 followed by gemcitabine 1000 mg/m^2 by intravenous infusion (IV) on Days 1, 8 and 15 of each 28 day cycle. Followed by nal-IRI (ONIVYDE®) 70 mg/m^2 followed by leucov

DRUG: Gemcitabine

  • Administered by intravenous infusion over 30 minutes.

DRUG: nab paclitaxel

  • Administered by intravenous infusion over 30-40 minutes.

DRUG: Onivyde

  • Administered by intravenous infusion over 90 minutes.

DRUG: Leucovorin

  • Administered by intravenous infusion over 30 minutes.

DRUG: 5-fu

  • Administered by intravenous infusion over 46 hours.
Primary Outcome MeasuresMeasure DescriptionTime Frame
Treatment safety as assessed by CTCAE v4.03Toxicities are evaluated according to CTCAE v4.03An average of 1 year
Secondary Outcome MeasuresMeasure DescriptionTime Frame
Overall survivalOS is defined as the time between the date of enrollment and the date of death (whatever the cause).5 years
Progression free survival (PFS)PFS is defined as the time between the date of enrollment and the date of the first radiological and/or pathological progression. Progression is assessed by investigator according to RECIST v1.1 criteria.5 years
Response rateResponse rate will be assessed per RECIST v1.1 criteria and CA19-9 over the entire treatment period.An average of 1 year

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Vincent J Picozzi, MD

Phone Number: 206-223-6193

Email: Vincent.Picozzi@virginiamason.org

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    Inclusion Criteria:
    1. Pathologically proven resectable or borderline resectable pancreatic cancer per current NCCN criteria (http://www.nccn.org/professionals/physician\_gls/f\_guidelines.asp). 2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0/1. 3. Adequate bone marrow reserves as evidenced by:

  • absolute neutrophil count (ANC) ≥1,500 cells/μl without the use of hematopoietic growth factors; and
  • Platelet count ≥100,000 cells/μl; and
  • Hemoglobin ≥9 g/dL (blood transfusions are permitted for patients with hemoglobin levels below 9 g/dL). 4. Adequate hepatic function as evidenced by:


  • Serum total bilirubin within normal range for the institution (biliary drainage is allowed for biliary obstruction); and
  • aspartate aminotransferase (AST) and alanine aminotransferase (ALT)


  • 2.5 x upper limit of normal (ULN) (≤5 x ULN is acceptable if liver metastases are present). 5. Adequate renal function as evidenced by a serum creatinine ≤1.5 x ULN. 6. At least 18 years of age. 7. Women of child-bearing potential (defined as a sexually mature woman who (1) has not undergone hysterectomy [the surgical removal of the uterus] or bilateral oophorectomy [the surgical removal of both ovaries] or (2) has not been naturally postmenopausal for at least 24 consecutive months [i.e., has had menses at any time during the preceding 24 consecutive months]) must: Either commit to true abstinence from heterosexual contact (which must be reviewed on a monthly basis), or agree to use, and be able to comply with, effective contraception without interruption for 28 days prior to starting study medications (including dose interruptions) and for 3 months after last dose of study medication and Have a negative pregnancy test result at screening and agree to ongoing pregnancy testing at the Investigator's discretion during the course of the study. This applies even if the subject practices true abstinence from heterosexual contact. 8. Male subjects must practice true abstinence or agree to use a condom during sexual contact with a female of childbearing potential or a pregnant female while on treatment (including during dose interruptions) with study medications and for 3 months following the last dose of study medication, even if he has undergone a successful vasectomy.

    • Exclusion Criteria:
    1. Prior therapy for pancreatic cancer (e.g., attempted surgery, chemotherapy, radiation therapy). 2. Any contraindication to curative surgery. 3. History of any second malignancy in the last 5 years except in-situ cancer or basal or squamous cell skin cancer. Subjects with history of other malignancies are eligible if they have been continuously disease free for at least 5 years. 4. Severe arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before study participation. 5. New York Heart Association (NYHA) Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure. 6. Active infection or an unexplained fever >38.5°C during screening visit or on the first scheduled day of dosing in each cycle which, in the Investigator's opinion, might compromise the subject's participation in the trial or affect the study outcome. Subjects with tumor fever may be enrolled at the discretion of the Investigator. 7. Known hypersensitivity to any of the components of nal-IRI, other liposomal products, fluoropyrimidines or leucovorin. 8. Neuropathy > grade 1. 9. Investigational therapy administered within 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior to the first scheduled day of dosing in this study. 10. Any other medical or social condition deemed by the Investigator to be likely to interfere with a subject's ability to sign informed consent, cooperate and/or participate in the study in any way, or interfere with the interpretation of the results. 11. Inability or unwillingness to provide written informed consent. 12. Patients who are not appropriate candidates for participation in this clinical study for any other reason as determined by the investigator.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

    • PRINCIPAL_INVESTIGATOR: Vincent J Picozzi, MD, Virginia mason medical Center

    Publications

    The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

    General Publications

    No publications available

    NPCF Pop up

    Make-A-Will Month

    Snag 6508be92
    Learn More
    Donate Now Online
    Other Ways to Donate